Keeping physicians up-to-date on the rapidly evolving field of targeted therapies and personalized medicine.

Dr Burke on MRD Testing in CLL and Myeloma
7:00
Dr Burke on MRD Testing in CLL and Myeloma
The Exciting Potential of Trispecific Antibodies in Myeloma
4:22
The Exciting Potential of Trispecific Antibodies in Myeloma
Sustaining Cancer Research and Oncology: A Call to Congress
6:34
Sustaining Cancer Research and Oncology: A Call to Congress
Dr. Burke Discusses the STARGLO and AQUILA Trials | Chief Insights in Oncology
6:41
Dr. Burke Discusses the STARGLO and AQUILA Trials | Chief Insights in Oncology
Telemedicine Expands Access to Trials for Rare Pancreatic Cancer
8:53
Telemedicine Expands Access to Trials for Rare Pancreatic Cancer
Dr Turk Delves Into CRC Updates From ASCO 2025
4:35
Dr Turk Delves Into CRC Updates From ASCO 2025
ASCO 2025: Expert Insights & Top Abstracts Across Cancers
9:37
ASCO 2025: Expert Insights & Top Abstracts Across Cancers
ASCO25 GI Malignancies: Key Updates With Dr Loaiza-Bonilla
29:48
ASCO25 GI Malignancies: Key Updates With Dr Loaiza-Bonilla
The Future of Cancer Research: Insights From Dr Ferris
4:40
The Future of Cancer Research: Insights From Dr Ferris
ASCO25: cSSC & Melanoma Advances With Dr. In
30:46
ASCO25: cSSC & Melanoma Advances With Dr. In
​​Prostate Cancer: Key Insights from AUA 2025
7:25
​​Prostate Cancer: Key Insights from AUA 2025
The Future of CAR T-Cell Therapy: Insights From ASCO GI and EHA/EBMT
5:31
The Future of CAR T-Cell Therapy: Insights From ASCO GI and EHA/EBMT
Advances in Urologic Oncology and the Evolving Role of the Surgeon
3:44
Advances in Urologic Oncology and the Evolving Role of the Surgeon
Dr Burke Pinpoints Top Trends from ASH 2024
9:45
Dr Burke Pinpoints Top Trends from ASH 2024
Controversy Over Adjuvant CDK4/6 Inhibitors in HER2-Negative Breast Cancer
5:01
Controversy Over Adjuvant CDK4/6 Inhibitors in HER2-Negative Breast Cancer
Optimizing Hematologic Care With Real-World Data
3:36
Optimizing Hematologic Care With Real-World Data
Top Anticipations for ASH 2024: Oncologists Share Key Highlights to Watch
3:38
Top Anticipations for ASH 2024: Oncologists Share Key Highlights to Watch
Initiating The Discussion on Informative Censoring in Clinical Trials
7:52
Initiating The Discussion on Informative Censoring in Clinical Trials
Expert Takeaway From WCLC Congress Involving Innovative Bispecific Antibody for NSCLC
3:18
Expert Takeaway From WCLC Congress Involving Innovative Bispecific Antibody for NSCLC
AI Model (DeepHRD) Bests Standard Tests in Predicting HRD
4:09
AI Model (DeepHRD) Bests Standard Tests in Predicting HRD
The Impact of Weight-loss Treatments on Cancer in The US
3:23
The Impact of Weight-loss Treatments on Cancer in The US
Oncologists Share Breakthroughs From the 2024 World Conference on Lung Cancer
4:14
Oncologists Share Breakthroughs From the 2024 World Conference on Lung Cancer
Emerging Experts: A Discussion With Tarantino on HER2-Low Breast Cancer and Antibody-Drug Conjugates
30:50
Emerging Experts: A Discussion With Tarantino on HER2-Low Breast Cancer and Antibody-Drug Conjugates
CRISPR Technology Explored in Oncology
6:46
CRISPR Technology Explored in Oncology
AI Advances Enable Digital Twin as SOC Control in GVHD Clinical Trials
9:10
AI Advances Enable Digital Twin as SOC Control in GVHD Clinical Trials
Navigating the Newly, Revealed World of MDS
3:11
Navigating the Newly, Revealed World of MDS
Combining New Therapies and MRD Approaches Across Lymphomas
3:02
Combining New Therapies and MRD Approaches Across Lymphomas
Comparing Afami-cel With Existing Treatments in Synovial Sarcoma
2:09
Comparing Afami-cel With Existing Treatments in Synovial Sarcoma
Should Frontline Myeloma Treatment Include a 3- or 4-Drug Regimen?
1:02
Should Frontline Myeloma Treatment Include a 3- or 4-Drug Regimen?
Immunotherapy Combinations Improve Survival in Advanced Renal Cell Carcinoma
1:37
Immunotherapy Combinations Improve Survival in Advanced Renal Cell Carcinoma